Evidence map›Paper›PMID 23658855›Full record

ArticleCancers2010

Galectins as cancer biomarkers.

Vitaly Balan, Pratima Nangia-Makker, Avraham Raz

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 74 citations in OpenAlex.

  1. Galectins and Liver Diseases.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Article
  4. Galectin-8, cytokines, and the storm.Biochemical Society transactions · 2022
    Review
  5. Review
  6. Article
  7. Article
  8. The roles of galectins in hepatic diseases.Journal of molecular histology · 2020
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Galectin-7 in Epithelial Homeostasis and Carcinomas.International journal of molecular sciences · 2017
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Vitaly BalanKarmanos Cancer Institute, Wayne State University, 110 E. Warren Avenue, Detroit, MI 48201, USA.
Pratima Nangia-Makker
Avraham Raz
The Barbara Ann Karmanos Cancer Institute · USWayne State University · US

Funding

The Role of Tumor Cell Surface Lectin in MetastasesR37CA046120 · NCI · WAYNE STATE UNIVERSITY · PI RAZ, AVRAHAM · 2007 to 2014
$3.0M
TUMOR CELL SURFACE LECTIN AND METASTASISR01CA046120 · NCI · WEIZMANN INSTITUTE OF SCIENCE · PI RAZ, AVRAHAM · 1987 to 2006
$2.0M
NCI NIH HHS R01 CA046120NCI NIH HHS R37 CA046120
6 · The paper itself

Abstract

Galectins are a group of proteins that bind β-galactosides through evolutionarily conserved sequence elements of the carbohydrate recognition domain (CRD). Proteins similar to galectins can be found in very primitive animals such as sponges. Each galectin has an individual carbohydrate binding preference and can be found in cytoplasm as well as in the nucleus. They also can be secreted through non-classical pathways and function extracellularly. Experimental and clinical data demonstrate a correlation between galectin expression and tumor progression and metastasis, and therefore, galectins have the potential to serve as reliable tumor markers. In this review, we describe the expression and role of galectins in different cancers and their clinical applications for diagnostic use.

Indexed as

biomarkerscancergalectins

Identifiers

PMID23658855
PMCPMC3645499
OpenAlexW2167840184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.